HC Wainwright & Co. Reiterates Buy on CymaBay Therapeutics, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on CymaBay Therapeutics (NASDAQ:CBAY) and maintained a price target of $21.
September 07, 2023 | 1:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CymaBay Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $21.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for CymaBay Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100